Trial Termination and Drug Misclassification in Sequential Adaptive Clinical Trials

References

• Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ (2009) I-Spy 2: An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin. Pharmacol. Therapeut. 86(1):97–100.Crossref, Google Scholar
• Bassler D, Montori VM, Briel M, Glasziou P, Guyatt G (2008) Early stopping of randomized clinical trials for overt efficacy is problematic. J. Clin. Epidemiol. 61(3):241–246.Crossref, Google Scholar
• Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, Heels-Ansdell D, Walter SD, Guyatt GH, Group S-S (2010) Stopping randomized trials early for benefit and estimation of treatment effects: Systematic review and meta-regression analysis. JAMA 303(12):1180–1187.Crossref, Google Scholar
• Bellissant E, Benichou J, Chastang C (1990) Application of the triangular test to phase II cancer clinical trials. Statist. Med. 9(8):907–917.Crossref, Google Scholar
• Berry DA (2011a) Adaptive clinical trials in oncology. Nature Rev. Clin. Oncol. 9(4):199–207.Crossref, Google Scholar
• Berry DA (2011b) Adaptive clinical trials: The promise and the caution. J. Clin. Oncol. 29(6):606–609.Crossref, Google Scholar
• Bland JM, Altman DG (2000) The odds ratio. BMJ 320(7247):1468.Crossref, Google Scholar
• Chow S-C, Chang M (2008) Adaptive design methods in clinical trials—A review. Orphanet J. Rare Diseases 3(11):169–190.Google Scholar
• Chow S-C, Chang M (2011) Adaptive Design Methods in Clinical Trials (CRC Press, Boca Raton, FL).Crossref, Google Scholar
• Chow S-C, Liu J-P (2008) Design and Analysis of Clinical Trials: Concepts and Methodologies (John Wiley & Sons, Hoboken, NJ).Google Scholar
• Crowley J, Hoering A (2012) Handbook of Statistics in Clinical Oncology (CRC Press, Boca Raton, FL).Google Scholar
• David E, Tramontin T, Zemmel R (2009) Pharmaceutical R&D: The road to positive returns. Nature Rev. Drug Discovery 8(8):609–610.Crossref, Google Scholar
• Denrell J (2007) Adaptive learning and risk taking. Psych. Rev. 114(1):177–187.Crossref, Google Scholar
• Denrell J, Le Mens G (2011) Seeking positive experiences can produce illusory correlations. Cognition 119(3):313–324.Crossref, Google Scholar
• Denrell J, March JG (2001) Adaptation as information restriction: The hot stove effect. Organ. Sci. 12(5):523–538.Link, Google Scholar
• DiMasi JA, Grabowski HG, Hansen RW (2016) Innovation in the pharmaceutical industry: New estimates of R&D costs. J. Health Econom. 47:20–33.Crossref, Google Scholar
• Ding M, Eliashberg J, Stremersch S (2014) Innovation and Marketing in the Pharmaceutical Industry: Emerging Practices, Research, and Policies(Springer, New York).Crossref, Google Scholar
• Ellenberg SS, DeMets DL, Fleming TR (2010) Bias and trials stopped early for benefit. JAMA 304(2):158.Crossref, Google Scholar
• Ghaffarzadegan N, Lyneis J, Richardson GP (2011) How small system dynamics models can help the public policy process. System Dynam. Rev. 27(1):22–44.Google Scholar
• Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 349(19):1793–1802.Crossref, Google Scholar
• He P, Lai TL, Liao OY (2012) Futility stopping in clinical trials. Statist. Its Interface 5(4):415–423.Crossref, Google Scholar
• Huber GP (1991) Organizational learning: The contributing processes and the literatures. Organ. Sci. 2(1):88–115.Link, Google Scholar
• Hulot JS, Cucherat M, Charlesworth A, Van Veldhuisen DJ, Corvol JC, Mallet A, Boissel JP, Hampton J, Lechat P (2003) Planning and monitoring of placebo‐controlled survival trials: Comparison of the triangular test with usual interim analyses methods. Br. J. Clin. Pharmacol. 55(3):299–306.Crossref, Google Scholar
• Jitlal M, Khan I, Lee S, Hackshaw A (2012) Stopping clinical trials early for futility: Retrospective analysis of several randomised clinical studies. Br. J. Cancer 107(6):910–917.Crossref, Google Scholar
• Kim K, Demets DL (1987) Design and analysis of group sequential tests based on the type i error spending rate function. Biometrika 74(1):149–154.Crossref, Google Scholar
• Korn EL, Freidlin B, Mooney M (2010) Bias and trials stopped early for benefit. JAMA 304(2):157–158.Crossref, Google Scholar
• Lan KG, DeMets DL (1983) Discrete sequential boundaries for clinical trials. Biometrika 70(3):659–663.Crossref, Google Scholar
• Larson RC, Ghaffarzadegan N, Diaz MG (2012) Magnified effects of changes in NIH research funding levels. Service Sci. 4(4):382–395.Link, Google Scholar
• Lesaffre E, Edelman M, Hanna N, Park K, Thatcher N, Willemsen S, Gaschler-Markefski B, Kaiser R, Manegold C (2017) Statistical controversies in clinical research: Futility analyses in oncology–lessons on potential pitfalls from a randomised controlled trial. Ann. Oncol. 28(7):1419–1426.Crossref, Google Scholar
• McPherson K (1982) On choosing the number of interim analyses in clinical trials. Statist. Med. 1(1):25–36.Crossref, Google Scholar
• Montori VM, Devereaux P, Adhikari NK, Burns KE, Eggert CH, Briel M, Lacchetti C, et al.. (2005) Randomized trials stopped early for benefit: A systematic review. JAMA 294(17):2203–2209.Crossref, Google Scholar
• O’Brien PC, Fleming TR (1979) A multiple testing procedure for clinical trials. Biometrics 35(3):549–556.Crossref, Google Scholar
• Orloff J, Douglas F, Pinheiro J, Levinson S, Branson M, Chaturvedi P, Ette E, Gallo P, Hirsch G, Mehta C (2009) The future of drug development: Advancing clinical trial design. Nature Rev. Drug Discovery 8(12):949–957.Crossref, Google Scholar
• Park H, Clear T, Rouse WB, Basole RC, Braunstein ML, Brigham KL, Cunningham L (2012) Multilevel simulations of health delivery systems: A prospective tool for policy, strategy, planning, and management. Service Sci. 4(3):253–268.Link, Google Scholar
• Patel NR, Ankolekar S, Antonijevic Z, Rajicic N (2013) A mathematical model for maximizing the value of phase 3 drug development portfolios incorporating budget constraints and risk. Statist. Medicine 32(10):1763–1777.Crossref, Google Scholar
• Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL (2010) How to improve R&D productivity: The pharmaceutical industry’s grand challenge. Nature Rev. Drug Discovery 9(3):203–214.Crossref, Google Scholar
• Pharmaceutical Research and Manufacturers of America (2018) 2017 PhRMA Annual Membership Survey. Accessed March 2, 2018, http://phrma-docs.phrma.org/files/dmfile/PhRMA_membership-survey_2017.pdf.Google Scholar
• Pocock SJ (1977) Group sequential methods in the design and analysis of clinical trials. Biometrika 64(2):191–199.Crossref, Google Scholar
• Pocock SJ (1982) Interim analyses for randomized clinical trials: The group sequential approach. Biometrics 38(1):153–162.Crossref, Google Scholar
• Pocock SJ (2005) When (not) to stop a clinical trial for benefit. JAMA 294(17):2228–2230.Crossref, Google Scholar
• Pocock S, White I (1999) Trials stopped early: Too good to be true? Lancet 353(9157):943–944.Crossref, Google Scholar
• Pocock S, Wang D, Wilhelmsen L, Hennekens CH (2005) The data monitoring experience in the candesartan in heart failure assessment of reduction in mortality and morbidity (charm) program. Amer. Heart J. 149(5):939–943.Crossref, Google Scholar
• Rogers MS, Chang AM, Todd S (2005) Using group‐sequential analysis to achieve the optimal sample size. Internat. J. Obstetrics Gynaecology 112(5):529–533.Crossref, Google Scholar
• Schou IM, Marschner IC (2013) Meta‐analysis of clinical trials with early stopping: An investigation of potential bias. Statist. Med. 32(28):4859–4874.Crossref, Google Scholar
• Sebille V, Bellissant E (2000) Comparison of four sequential methods allowing for early stopping of comparative clinical trials. Clin. Sci. 98(5):569–578.Crossref, Google Scholar
• Siegmund D (1979) Corrected diffusion approximations in certain random walk problems. Advances Appl. Probab. 11(4):701–719.Crossref, Google Scholar
• Szumilas M (2010) Explaining odds ratios. J. Canadian Acad. Child Adolescent Psychiatry 19(3):227–229.Google Scholar
• Tobias JS, Monson K, Gupta N, MacDougall H, Glaholm J, Hutchison I, Kadalayil L, Hackshaw A (2010) Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK head and neck (Ukhan1) trial. Lancet Oncol. 11(1):66–74.Crossref, Google Scholar
• Todd S, Whitehead A, Stallard N, Whitehead J (2001) Interim analyses and sequential designs in phase III studies. Br. J. Clin. Pharmacol. 51(5):394–399.Crossref, Google Scholar
• UKCCCR Anal Cancer Trial Working Party (1996) Epidermoid anal cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet 348(9034):1049–1054.Crossref, Google Scholar
• US Food and Drug Administration (2010) Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics (Food and Drug Administration, Washington, DC).Google Scholar
• US Food and Drug Administration (2011) Oncologic Drugs Advisory Committee (Odac) meeting report. Accessed May 28, 2015, http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM245644.pdf.Google Scholar
• US Food and Drug Administration (2014) Fast track, accelerated approval, and priority review. Accessed May 28, 2015, http://www.fda.gov/ForPatients/Approvals/Fast/ucm405447.htm.Google Scholar
• Van Der Tweel I, Van Noord PA (2003) Early stopping in clinical trials and epidemiologic studies for “futility”: Conditional power vs. sequential analysis. J. Clin. Epidemiol. 56(7):610–617.Crossref, Google Scholar
• Whitehead J (1997) The Design and Analysis of Sequential Clinical Trials (John Wiley & Sons, Chichester, UK).Crossref, Google Scholar
• Whitehead J (2002) Sequential methods in clinical trials. Sequential Anal. 21(4):285–308.Crossref, Google Scholar
• Whitehead J (2004) Stopping clinical trials by design. Nature Rev. Drug Discovery 3(11):973–977.Crossref, Google Scholar
• Whitehead J, Todd S (2004) The double triangular test in practice. Pharmaceutical Statist. 3(1):39–49.Crossref, Google Scholar
• Wittes J (1993) Behind closed doors: The data monitoring board in randomized clinical trials. Statist. Med. 12(5–6):419–424.Crossref, Google Scholar
• Zannad F, Stough WG, McMurray JJ, Remme WJ, Pitt B, Borer JS, Geller NL, Pocock SJ (2012) When to stop a clinical trial early for benefit: Lessons learned and future approaches. Circulation: Heart Failure 5(2):294–302.Crossref, Google Scholar